{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:14:00Z","timestamp":1763104440370,"version":"3.45.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Middle East respiratory syndrome coronavirus (MERS-CoV) poses an ongoing public health risk with a 36% case-fatality rate and no licensed vaccines. This Phase 2a, randomized, blinded, placebo-controlled, multi-center trial (MERS-201; NCT04588428) evaluated the safety, tolerability, and immunogenicity of INO-4700, a DNA vaccine against the MERS-CoV spike glycoprotein, in healthy adult volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants received INO-4700 or placebo intradermally followed by electroporation upon enrollment into any one of five active treatment groups, resulting from three-dose levels (0.6 mg, 1 mg, and 2 mg total) during each of two dosing days or four placebo groups. Doses were administered as 1 or 2 concurrent injections to achieve the total dose level at Week 0 and at either Week 4 or 8. Safety endpoints included incidence of treatment-emergent adverse events (TEAEs), their toxicity grading scale, seriousness, and relationship to study treatment and AEs of special interest (AESI). Immunogenicity endpoints included evaluation of humoral and cellular immune responses, assessed pre-dose (Screening and\/or Week 0) and at Weeks 6 and 10.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and ninety-two participants were randomized across the nine study groups and followed up between June 2021 and January 2023. Treatment with INO-4700 was well-tolerated and had a favorable safety profile with low incidence of TEAEs, which were overall similar between INO-4700 and placebo groups, with most of the TEAEs assessed as Grade 1 or Grade 2, non-serious, and unrelated to treatment. Group E, the highest INO-4700 dose tested (2 mg total), showed greater immune responses compared to other groups, with significantly elevated MERS-CoV receptor-binding domain (RBD) and spike-binding IgG levels, and seroreactivity at Week 10 peaking at 42% and 32%, respectively. Spike-specific T cell responses further contributed to INO-4700 immunogenicity, ranging from 29% in Group C to 50% in Group E.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DNA vaccine INO-4700 was well-tolerated in healthy adults across all groups after each dose was administered and elicited humoral and cellular immune responses. These results warrant further evaluation of INO-4700 as a candidate vaccine for MERS-CoV outbreak preparedness and prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      ,\n                      <jats:bold>identifier NCT04588428<\/jats:bold>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1662923","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:11:29Z","timestamp":1763104289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers"],"prefix":"10.3389","volume":"16","author":[{"given":"Joseph T.","family":"Agnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahem S.","family":"Al-Ghraibeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleimman Ahmad","family":"Al-Sweedan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josphat","family":"Kosgei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhards","family":"Ogutu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShuPing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventure","family":"Orizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate E.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Kraynyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Liebowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent M.","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/17460441.2023.2192921","article-title":"An overview of the recent progress in middle east respiratory syndrome coronavirus (MERS-CoV) drug discovery","volume":"18","author":"Kandeel","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03488-13","article-title":"Coronaviruses: important emerging human pathogens","volume":"88","author":"Coleman","year":"2014","journal-title":"J Virol"},{"key":"B3","unstructured":"WHO-Convened Global Study of Origins of SARS-CoV-2: China Part\n          \n          \n          2021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmsr1408795","article-title":"Middle east respiratory syndrome","volume":"376","author":"Arabi","year":"2017","journal-title":"New Eng J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7326\/m13-2486","article-title":"Clinical course and outcomes of critically ill patients with middle east respiratory syndrome coronavirus infection","volume":"160","author":"Arabi","year":"2014","journal-title":"Ann Intern Med"},{"key":"B6","unstructured":"Middle East Respiratory Syndrome Coronavirus - Kingdom of Saudi Arabia\n          \n          \n          \n          2025"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1358885","article-title":"Mucosal immunity in upper and lower respiratory tract to MERS-CoV","volume":"15","author":"Shrwani","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(21)00193-2","article-title":"Safety and immunogenicity of chAdOx1 MERS vaccine candidate in healthy middle eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial","volume":"3","author":"Bosaeed","year":"2022","journal-title":"Lancet Microbe"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109998","article-title":"Safety and immunogenicity of the chAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-coV vaccines","volume":"118","author":"Kandeel","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal syncon ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-zika virus DNA vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-middle east respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.015","article-title":"Vaccine development for emerging virulent infectious diseases","volume":"35","author":"Maslow","year":"2017","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/srep12616","article-title":"Protection against dengue disease by synthetic nucleic acid antibody prophylaxis\/immunotherapy","volume":"5","author":"Flingai","year":"2015","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2204841119","DOI":"10.1073\/pnas.2204841119","article-title":"Toward a precision medicine approach for autoimmunity","volume":"119","author":"Kissler","year":"2022","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s43856-024-00684-8","article-title":"The DNA-based lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal lassa fever","volume":"4","author":"Andrade","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against lassa fever","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1382780","article-title":"DNA vaccines elicit durable protective immunity against individual or simultaneous infections with lassa and ebola viruses in Guinea pigs","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1987","article-title":"Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus-associated recurrent\/metastatic head and neck squamous cell carcinoma","volume":"29","author":"Aggarwal","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41467-025-56729-6","article-title":"DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1\/2 study assessing efficacy, safety, and immunogenicity of INO-3107","volume":"16","author":"Morrow","year":"2025","journal-title":"Nat Commun"},{"key":"B22","unstructured":"World\u2019s First Plasmid-Based DNA COVID-19 Vaccine Received Emergency Use Authorization in India\n          \n          \n          \n          2025"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against middle east respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci Trans Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e146082","DOI":"10.1172\/jci.insight.146082","article-title":"Intradermal delivery of a synthetic DNA vaccine protects macaques from middle east respiratory syndrome coronavirus","volume":"6","author":"Patel","year":"2021","journal-title":"JCI Insight"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30397-4","article-title":"First clinical trial of a MERS coronavirus DNA vaccine","volume":"19","author":"Yoon","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1586\/14760584.2015.990890","article-title":"Electroporation-enhanced delivery of nucleic acid vaccines","volume":"14","author":"Broderick","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B29","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Biologics Evaluation and Research. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. September 2007\n          \n          \n          2025"},{"key":"B30","unstructured":"Establishment of 1st WHO International Standard for Anti-MERS-CoV Antibody\n          \n          \n            \n              Mattiuzzo\n              G\n            \n            \n              Bentley\n              E\n            \n            \n              Seo\n              SH\n            \n          \n          \n          2020"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001438","article-title":"Genome-wide B cell, CD4+, and CD8+ T cell epitopes that are highly conserved between human and animal coronaviruses, identified from SARS-CoV-2 as targets for preemptive pan-coronavirus vaccines","volume":"206","author":"Prakash","year":"2021","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030564","article-title":"The influence of cross-reactive T cells in COVID-19","volume":"12","author":"Eggenhuizen","year":"2024","journal-title":"Biomedicines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"B34","unstructured":"Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers\n          \n          \n          \n          2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70330","DOI":"10.7554\/eLife.70330","article-title":"Cross-reactive antibodies after SARS-CoV-2 infection and vaccination","volume":"10","author":"Grobben","year":"2021","journal-title":"Elife"},{"key":"B36","unstructured":"WHO Target Product Profiles for MERS-CoV Vaccines\n          \n          \n          \n          2017"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3390\/cells9122638","article-title":"Comprehensive structural and molecular comparison of spike proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and their interactions with ACE2","volume":"9","author":"Hatmal","year":"2020","journal-title":"Cells"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662923\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:11:33Z","timestamp":1763104293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662923\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1662923"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1662923","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1662923"}}